Additional in vivo studies have demonstrated that blocking AXL can suppress the growth of FLT3-ITD AML [17], decrease tumor size [16], and block the activation of cellular survival pathways while upregulating the apoptotic pathway [16]. This evidence concerns the gene FLT3 and acute myeloid leukemia.